As a well-known immune target, immunotherapy with the blockade of PD1 and its ligand PD-L1 can improve the survival time of patients with lung cancer (De Ruysscher et al., 2022) and colorectal cancer (Andre et al., 2020). Here, PDCD1 is linked to lung cancer.